The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
Open accessAbstract
Alzheimer's disease and Parkinson's disease are associated with the cerebral accumulation of β-amyloid and α-synuclein, respectively. Some patients have clinical and pathological features of both diseases, raising the possibility of overlapping pathogenetic pathways. We generated transgenic (tg) mice with neuronal expression of human β-amyloid peptides, α-synuclein, or both. The functional and morphological alterations in doubly tg mice resembled the Lewy-body variant of Alzheimer's disease. These mice had severe deficits in learning and memory, developed motor deficits before α-synuclein singly tg mice, and showed prominent age-dependent degeneration of cholinergic neurons and presynaptic terminals. They also had more α-synuclein-immunoreactive neuronal inclusions than α-synuclein singly tg mice. Ultrastructurally, some of these inclusions were fibrillar in doubly tg mice, whereas all inclusions were amorphous in α-synuclein singly tg mice. β-Amyloid peptides promoted aggregation of α-synuclein in a cell-free system and intraneuronal accumulation of α-synuclein in cell culture. β-Amyloid peptides may contribute to the development of Lewy-body diseases by promoting the aggregation of α-synuclein and exacerbating α-synuclein-dependent neuronal pathologies. Therefore, treatments that block the production or accumulation of β-amyloid peptides could benefit a broader spectrum of disorders than previously anticipated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“The hαSyn/hAPP model recapitulated many of the clinical symptoms and pathology of AD-LBV.”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Further evidence of a link between αSyn and Aβ pathology was offered from studies using mice expressing wt human αSyn (hαSyn) and human APP (hAPP) (hαSyn/hAPP).”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Self-citationMcKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citationA Drosophila model of Parkinson's disease
Feany, M. Β., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,157
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,073
Flagged first, then by citations
Research works printed but not linked: 3
- R D Terry, R Katzman, K L Bick, S S Sisodia Alzheimer Disease (Lippincott, Philadelphia, 1999).
- A Takeda, M Mallory, M Sundsmo, W Honer, L Hansen, E Masliah Am J Pathol 152, 367–372 (1998).
- D Van Gool, B De Strooper, F Van Leuven, R Dom Dementia 6, 63–68 (1995).
Cited by
Sorted by citations
Items 101–200 of 607
A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides
Gallardo, G., Schlüter, O. M., & Südhof, T. C. (2008) · Nature Neuroscience · doi:10.1038/nn2058 · Cited by 145
Current Progress of RNA Aptamer-Based Therapeutics
Zhou, J., Bobbin, M. L., Burnett, J., & Rossi, J. J. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00234 · Cited by 140
Brain cholinergic vulnerability: Relevance to behavior and disease
McKinney, M. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.05.019 · Cited by 140
Examining the mechanisms that link β-amyloid and α-synuclein pathologies
Marsh, S. E., & Blurton-Jones, M. M. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt109 · Cited by 140
Amyloid-β and Parkinson’s disease
Kings Parcog groupMDS Nonmotor study group, Lim, E. W., Aarsland, D., Ffytche, D. H., Taddei, R. N., van Wamelen, D. J., Wan, Y.-M., Tan, E. K., & Chaudhuri, К. R. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9100-8 · Cited by 143
Dawson, T. M., Mandir, A. S., & Lee, M. K. (2002) · Neuron · doi:10.1016/s0896-6273(02)00780-8 · Cited by 137
D -Galactose Effectiveness in Modeling Aging and Therapeutic Antioxidant Treatment in Mice
Parameshwaran, K., Irwin, M. H., Steliou, K., & Pinkert, C. A. (2010) · Rejuvenation Research · doi:10.1089/rej.2010.1020 · Cited by 135
Fundamentals of cross-seeding of amyloid proteins: an introduction
Ren, B., Zhang, Y., Zhang, M., Liu, Y., Zhang, D., Gong, X., Feng, Z., Tang, J., Chang, Y., & Zheng, J. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb01871a · Cited by 139
Enteric alpha‐synuclein expression is increased in Parkinson's disease but not Alzheimer's disease
Gold, A., Turkalp, Z. T., & Munoz, D. G. (2013) · Movement Disorders · doi:10.1002/mds.25298 · Cited by 132
Synaptic remodeling during aging and in Alzheimer's disease
Masliah, E., Crews, L., & Hansen, L. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s311 · Cited by 132
Self-citationKaur, S., Junek, A., Black, M. A., & Semba, K. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.1585-07.2008 · Cited by 129
Valera, E., Spencer, B. J., & Masliah, E. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0397-z · Cited by 135
Self-citationRETRACTED: Soluble α-Synuclein Is a Novel Modulator of Alzheimer's Disease Pathophysiology
Larson, M. E., Sherman, M. A., Greimel, S., Kuskowski, M., Schneider, J. A., Bennett, D. A., & Lesné, S. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0581-12.2012 · Cited by 128
RetractedInteraction between pathogenic proteins in neurodegenerative disorders
Jellinger, K. A. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01507.x · Cited by 132
Tau and α-Synuclein Pathology in Amygdala of Parkinsonism-Dementia Complex Patients of Guam
Forman, M. S., Schmidt, M. L., Kasturi, S. S., Perl, D. P., Lee, V. M. ‐., & Trojanowski, J. Q. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61119-4 · Cited by 127
General aspects of neurodegeneration
Jellinger, K. A. (2003) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-0643-3_7 · Cited by 126
α-Synucleinopathy models and human neuropathology: similarities and differences
Kahle, P. J. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0302-x · Cited by 132
The potential use of mesenchymal stem cells and their exosomes in Parkinson’s disease treatment
Mosaddeghi-Heris, R., Shirvaliloo, M., Abbaspour‐Aghdam, S., Hazrati, A., Shariati, A., Youshanlouei, H. R., Jadidi‐Niaragh, F., Valizadeh, H., & Ahmadi, M. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03050-4 · Cited by 123
Amyloid PET Imaging in Lewy Body Disorders
Donaghy, P. C., Thomas, A. J., & O'Brien, J. T. (2013) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2013.03.001 · Cited by 118
Chapter 6 Molecular and Cellular Biology of Synucleins
Surguchov, A. P. (2008) · International review of cytology · doi:10.1016/s1937-6448(08)01406-8 · Cited by 123
Amyloid-beta and tau protein beyond Alzheimer’s disease
Abyadeh, M., Gupta, V., Paulo, J. A., Mahmoudabad, A. G., Shadfar, S., Mirshahvaladi, S., Gupta, V. B., Nguyen, C. T. O., Finkelstein, D. I., You, Y., et al. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.386406 · Cited by 126
The role of intracellular amyloid β in Alzheimer's disease
Li, M. C., Chen, L., Lee, D. H. S., Yu, L., & Zhang, Y. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.08.002 · Cited by 118
Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved
Vasili, E., Dominguez‐Meijide, A., & Outeiro, T. F. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00107 · Cited by 121
γ-Synucleinopathy: neurodegeneration associated with overexpression of the mouse protein
Ninkina, N. N., Peters, O. M., Millership, S. J., Salem, H., van der Putten, H., & Buchman, V. L. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp090 · Cited by 115
Lee, J., Park, H., Park, B., Song, S. K., Sohn, Y. H., Lee, J. D., & Lee, P. H. (2009) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.184747 · Cited by 114
Koob, A. O., Ubhi, K. K., Paulsson, J. F., Kelly, J. W., Rockenstein, E. M., Mante, M., Adame, A., & Masliah, E. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.11.015 · Cited by 113
Self-citationAltered synaptic function in Alzheimer's disease
Bell, K. F. S., & Cuello, A. C. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.045 · Cited by 117
Alzheimer's in 3D culture: Challenges and perspectives
D'Avanzo, C., Aronson, J., Kim, Y. H., Choi, S. H., Tanzi, R. E., & Kim, D. Y. (2015) · BioEssays · doi:10.1002/bies.201500063 · Cited by 111
Trist, B. G., Davies, K. M., Cottam, V., Genoud, S., Ortega, R., Roudeau, S., Carmona, A., Silva, K. D., Wasinger, V. C., Lewis, S. J. G., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1726-6 · Cited by 115
α-Synuclein modulates tau spreading in mouse brains
Bassil, F., Meymand, E. S., Brown, H. J., Xu, H. W., Cox, T. O., Pattabhiraman, S., Maghames, C. M., Wu, Q., Zhang, B., Trojanowski, J. Q., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192193 · Cited by 109
Structural and Functional Insights into α-Synuclein Fibril Polymorphism
Mehra, S., Gadhe, L. G., Bera, R., Sawner, A. S., & Maji, S. K. (2021) · Biomolecules · doi:10.3390/biom11101419 · Cited by 111
Interactions of Amyloidogenic Proteins
Giasson, B. I., Lee, V. M. ‐., & Trojanowski, J. Q. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:49 · Cited by 106
Biochemical Staging of Synucleinopathy and Amyloid Deposition in Dementia With Lewy Bodies
Deramecourt, V., Bombois, S., Maurage, C., Ghestem, A., Drobecq, H., Vanmechelen, E., Lebert, F., Pasquier, F., & Delacourte, A. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000205145.54457.ea · Cited by 109
Transgenic Models of α‐Synuclein Pathology
Hashimoto, M., Rockenstein, E. M., & Masliah, E. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07475.x · Cited by 108
Self-citationGrimm, S., Höhn, A., Davies, K. J. A., & Grune, T. (2010) · Free Radical Research · doi:10.3109/10715762.2010.512040 · Cited by 112
Gozal, E., Gozal, D., Pierce, W. M. J., Thongboonkerd, V., Scherzer, J. A., Sachleben, L. R., Brittian, K. R., Guo, S., Cai, J., & Klein, J. B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01134.x · Cited by 107
Toledo, J. B., Korff, A., Shaw, L. M. J., Trojanowski, J. Q., & Zhang, J. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1148-z · Cited by 106
Ferman, T. J., Aoki, N., Crook, J. E., Murray, M. E., Graff‐Radford, N. R., van Gerpen, J. A., Uitti, R. J., Wszołek, Z. K., Graff‐Radford, J., Pedraza, O., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.09.014 · Cited by 105
Tau phosphorylation increases in symptomatic mice overexpressing A30P α-synuclein
Frasier, M. A., Walzer, M., McCarthy, L., Magnuson, D. J., Lee, J. M., Haas, C. A., Kahle, P. J., & Wolozin, B. L. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.07.016 · Cited by 103
Compta, Y., Valente, T., Saura, J., Segura, B., Iranzo, Á., Serradell, M., Junqué, C., Tolosa, E. S., Valldeoriola, F., Muñoz, E., et al. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7560-z · Cited by 108
The Genetics of Dementia with Lewy Bodies: Current Understanding and Future Directions
Orme, T., Guerreiro, R. J., & Brás, J. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0874-y · Cited by 106
Jenner, P. G., Morris, H. R., Robbins, T. W., Goedert, M., Hardy, J., Ben‐Shlomo, Y., Bolam, J. P., Burn, D. J., Hindle, J. V., Brooks, D. J., et al. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130175 · Cited by 103
Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities
Visanji, N. P., Lang, A. E., & Kovács, G. G. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0172-x · Cited by 102
Increased sensitivity to MPTP in human α-synuclein A30P transgenic mice
Nieto, M., Gil-Bea, F. J., Dalfó, E., Cuadrado‐Tejedor, M., Cabodevilla, F., Sánchez, B., Catena, S., Sesma, T., Ribé, E. M., Ferrer, I., et al. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.04.010 · Cited by 100
Alpha-synuclein: a pathological factor with Aβ and tau and biomarker in Alzheimer’s disease
Shim, K. H., Kang, M. J., Youn, Y. C., An, S. S. A., & Kim, S. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01150-0 · Cited by 106
Animal models of amyloid‐β‐related pathologies in Alzheimer’s disease
Philipson, O., Lord, A., Gumucio, A., O'Callaghan, P. W., Lannfelt, L., & Nilsson, L. N. G. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07564.x · Cited by 101
The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias
Villemagne, V. L., Fodero‐Tavoletti, M. T., Pike, K. E., Cappai, R., Masters, C. L., & Rowe, C. C. (2008) · Molecular Neurobiology · doi:10.1007/s12035-008-8019-y · Cited by 103
Swirski, M., Miners, J. S., de Silva, R., Lashley, T., Ling, H., Holton, J. L., Révész, T., & Love, S. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0077-y · Cited by 98
Ruffmann, C., Calboli, F. C. F., Bravi, I., Gveric, D. O., Curry, L. K., de Smith, A. J., Pavlou, S., Buxton, J. L., Blakemore, A. I. F., Takousis, P., et al. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12294 · Cited by 100
α-Synuclein in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment
Korff, A., Liu, C., Ginghina, C., Shi, M., Zhang, J., & Initiative, F. T. A. D. N. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-130458 · Cited by 95
Rockenstein, E. M., Mante, M., Alford, M. F., Adame, A., Crews, L. A., Hashimoto, M., Esposito, L., Mucke, L., & Masliah, E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m507016200 · Cited by 93
Self-citationBiomarkers of cognitive decline in Parkinson's disease
Lin, C., & Wu, R. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.02.010 · Cited by 100
Mild Cognitive Impairment in Parkinson’s Disease—What Is It?
Weil, R. S., Costantini, A. A., & Schrag, A. E. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0823-9 · Cited by 94
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 97
Self-citationObi, K., Akiyama, H., Kondo, H., Shimomura, Y., Hasegawa, M., Iwatsubo, T., Mizuno, Y., & Mochizuki, H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2007.11.019 · Cited by 93
CSF tau and β-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders
Irwin, D. J., Xie, S. X., Coughlin, D. G., Nevler, N., Akhtar, R. S., McMillan, C. T., Lee, E. B., Wolk, D. A., Weintraub, D. A., Chen‐Plotkin, A. S., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005166 · Cited by 94
Spencer, B. J., Valera, E., Rockenstein, E. M., Overk, C., Mante, M., Adame, A., Zago, W. M., Seubert, P. A., Barbour, R., Schenk, D., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0410-8 · Cited by 91
Self-citationRetractedThe morbid anatomy of dementia in Parkinson’s disease
Kalaitzakis, M. E., & Pearce, R. K. B. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0597-x · Cited by 90
Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice
Xu, Y., Xu, K., Sun, Y., Liou, B., Quinn, B., Li, R.-H., Xue, L., Zhang, W., Setchell, K. D. R., Witte, D. P., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu105 · Cited by 88
Prion protein (PrPc) promotes β-amyloid plaque formation
Schwarze-Eicker, K., Keyvani, K., Goertz, N., Westaway, D. A., Sachser, N., & Paulus, W. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.10.004 · Cited by 92
Rockenstein, E. M., Torrance, M., Mante, M., Adame, A., Paulino, A., Rose, J. B., Crews, L. A., Moessler, H., & Masliah, E. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.20818 · Cited by 88
Self-citationSystem-based approaches to decode the molecular links in Parkinson's disease and diabetes
Santiago, J. A., & Potashkin, J. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.03.019 · Cited by 89
Kahle, P. J., Haass, C., Kretzschmar, H. A., & Neumann, M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01020.x · Cited by 86
Orth, M., & Tabrizi, S. J. (2003) · Movement Disorders · doi:10.1002/mds.10447 · Cited by 87
Nigrostriatal Dysfunction in Familial Alzheimer's Disease-Linked APPswe/PS1ΔE9 Transgenic Mice
Perez, S. E., Lazarov, O., Koprich, J. B., Chen, E., Rodriguez‐Menendez, V., Lipton, J. W., Sisodia, S. S., & Mufson, E. J. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.2773-05.2005 · Cited by 86
Adult Neurogenesis and Neurodegenerative Disease
Steiner, B., Wolf, S. A., & Kempermann, G. (2005) · Regenerative Medicine · doi:10.2217/17460751.1.1.15 · Cited by 87
α-Synuclein transgenic mice exhibit reduced anxiety-like behaviour
George, S., van den Buuse, M., Mok, S. S., Masters, C. L., Li, Q., & Culvenor, J. G. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.12.017 · Cited by 84
Role of Synucleins in Alzheimer’s Disease
Crews, L. A., Tsigelny, I. F., Hashimoto, M., & Masliah, E. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9073-6 · Cited by 85
Self-citationSpencer, B. J., Marr, R. A., Rockenstein, E. M., Crews, L. A., Adame, A., Potkar, R., Patrick, C., Gage, F. H., Verma, I. M., & Masliah, E. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-109 · Cited by 84
Self-citationActive immunization therapies for Parkinson's disease and multiple system atrophy
Schneeberger, A., Tierney, L., & Mandler, M. (2015) · Movement Disorders · doi:10.1002/mds.26377 · Cited by 86
Epilepsy in neurodegenerative diseases
Neri, S., Mastroianni, G., Gardella, E., Aguglia, U., & Rubboli, G. (2022) · Epileptic Disorders · doi:10.1684/epd.2021.1406 · Cited by 84
Santiago, J. A., & Potashkin, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083940 · Cited by 79
γ-Synuclein: Seeding of α-Synuclein Aggregation and Transmission between Cells
Surgucheva, I. G., Sharov, V. S., & Surguchov, A. P. (2012) · Biochemistry · doi:10.1021/bi300478w · Cited by 86
Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro
Köppen, J., Schulze, A., Machner, L., Wermann, M., Eichentopf, R., Guthardt, M., Hähnel, A., Klehm, J., Kriegeskorte, M.-C., Hartlage‐Rübsamen, M., et al. (2020) · Molecules · doi:10.3390/molecules25030580 · Cited by 79
Regional Overlap of Pathologies in Lewy Body Disorders
Colom‐Cadena, M., Grau‐Rivera, O., Planellás, L., Cerquera‐Cleves, C., Morenas‐Rodríguez, E., Helgueta, S., Muñoz, L., Kulisevsky, J., Martı́, M. J., Tolosa, E. S., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx002 · Cited by 80
Hashimoto, M., & Masliah, E. (2003) · Neurochemical Research · doi:10.1023/a:1026073324672 · Cited by 78
Self-citationAmyloid cross-seeding raises new dimensions to understanding of amyloidogenesis mechanism
Chaudhuri, P., Prajapati, K. P., Anand, B. G., Dubey, K., & Kar, K. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100937 · Cited by 80
Xie, Q. M., Yang, Y., Huang, J., Ninkovic, J., Walcher, T., Wolf, L. V., Vitenzon, A., Zheng, D., Götz, M., Beebe, D. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054507 · Cited by 79
A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain
Fujita, M., Sugama, S., Sekiyama, K., Sekigawa, A., Tsukui, T., Nakai, M., Waragai, M., Takenouchi, T., Takamatsu, Y., Wei, J., et al. (2010) · Nature Communications · doi:10.1038/ncomms1101 · Cited by 78
Self-citationJellinger, K. A. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_12 · Cited by 77
Dzwolak, W., Muraki, T., Katō, M., & Taniguchi, Y. (2004) · Biopolymers · doi:10.1002/bip.10582 · Cited by 78
Self-Assembling Peptides as Extracellular Matrix Mimics to Influence Stem Cell's Fate
Hellmund, K. S., & Koksch, B. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00172 · Cited by 77
Ikarashi, Y., Iizuka, S., Imamura, S., Yamaguchi, T., Sekiguchi, K., Kanno, H., Kawakami, Z., Yuzurihara, M., Kase, Y., & Takeda, S. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.1701 · Cited by 76
Kohli, B. M., Pflieger, D., Mueller, L. N., Carbonetti, G., Aebersold, R. H., Nitsch, R. M., & Konietzko, U. (2012) · Journal of Proteome Research · doi:10.1021/pr300123g · Cited by 77
Parkinson’s disease: a rethink of rodent models
Melrose, H. L., Lincoln, S. J., Tyndall, G. M., & Farrer, M. J. (2006) · Experimental Brain Research · doi:10.1007/s00221-006-0461-3 · Cited by 74
Pathophysiology of synuclein aggregation in Lewy body disease
Mukaetova‐Ladinska, E. B., & McKeith, I. G. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.014 · Cited by 74
Overk, C., Cartier, A. E., Shaked, G. M., Rockenstein, E. M., Ubhi, K. K., Spencer, B. J., Price, D. L., Patrick, C., Desplats, P., & Masliah, E. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-18 · Cited by 73
Self-citationRetractedFleming, S. M., Mulligan, C. K., Richter, F., Mortazavi, F., Lemesre, V., Frías, C., Zhu, C., Stewart, A. J., Gozes, I., Morimoto, B. H., et al. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2010.12.011 · Cited by 72
Kasote, D. M., Hegde, M. V., & Katyare, S. S. (2013) · BioFactors · doi:10.1002/biof.1093 · Cited by 73
Correlation between decreased CSF α-synuclein and Aβ1–42 in Parkinson disease
Buddhala, C., Campbell, M. C., Perlmutter, J. S., & Kotzbauer, P. T. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.043 · Cited by 72
Ciccone, L., Shi, C., di Lorenzo, D., Van Baelen, A.-C., & Tonali, N. (2020) · Molecules · doi:10.3390/molecules25102439 · Cited by 69
Cross Currents in Protein Misfolding Disorders: Interactions and Therapy
Morales, R., Green, K., & Soto, C. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789541998 · Cited by 72
Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Oczkowska, A., Kozubski, W. P., Lianeri, M., & Dorszewska, J. (2014) · Current Genomics · doi:10.2174/1389202914666131210205839 · Cited by 72
Prevalence of amyloid‐β deposition in the cerebral cortex in Parkinson's disease
Mastaglia, F. L., Johnsen, R. D., Byrnes, M. L., & Kakulas, B. A. (2002) · Movement Disorders · doi:10.1002/mds.10295 · Cited by 70
Lue, L., Walker, D. G., Adler, C., Shill, H. A., Tran, H., Akiyama, H., Sue, L., Caviness, J., Sabbagh, M. N., & Beach, T. G. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00585.x · Cited by 65
Joki, H., Higashiyama, Y., Nakae, Y., Kugimoto, C., Doi, H., Kimura, K., Kishida, H., Ueda, N., Nakano, T., Takahashi, T., et al. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.12.018 · Cited by 69
Prodromal dementia with L ewy bodies
Fujishiro, H., Nakamura, S., Sato, K., & Iseki, E. (2015) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.12466 · Cited by 68
Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses
Wilkaniec, A., Czapski, G. A., & Adamczyk, A. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13365 · Cited by 69
Fujishiro, H., Iseki, E., Higashi, S., Kasanuki, K., Murayama, N., Togo, T., Katsuse, O., Uchikado, H., Aoki, N., Kosaka, K., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.09.036 · Cited by 70
Han, S.-H., Park, J.-C., & Mook-Jung, I. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.004 · Cited by 67
Metadata
- Authors
- Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2001-09-25
- Volume
- 98
- Issue
- 21
- Pages
- 12245-12250
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC59799
- OpenAlex
- W2131710583
- Cited by
- 607
- References
- 56
- Citations by year
- 2026: 8 · 2025: 26 · 2024: 17 · 2023: 23 · 2022: 17 · 2021: 17 · 2020: 39 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 24 · 2015: 26 · 2014: 44 · 2013: 29 · 2012: 24
- FWCI
- 15.14
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-05-22)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- National Institutes of Health (AG5131, 5r29ag010869-05, AG‐18440, AG11385, AG10869)
- National Institute on Aging (AG-11385, R37AG018440, R37AG011385, R01AG018440, P50AG005131, AG-5131, AG 18440, AG10869, R01AG011385)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, alpha-synuclein, Alzheimer's disease, Parkinson's disease, Lewy body disease, transgenic mice, neuronal inclusions, alpha-synuclein aggregation, cholinergic neuron degeneration, motor impairment, learning and memory impairment, presynaptic terminals
- MeSH terms
- Age Factors, Alzheimer Disease, Animals, Cell Line, Disease Models, Animal, Female, Humans, Learning Disabilities, Male, Memory Disorders, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Parkinson Disease, Gene Expression, Amyloid beta-Peptides, Mice, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
